Condition (MeSH)
Hypercalcemia
ClinicalTrials.gov lists 50 trials for Hypercalcemia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
50 of the 50 trials are tagged with Hypercalcemia itself; the rest are tagged with a narrower condition beneath it.
When did Hypercalcemia trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 4 |
| 2017 | 1 |
| 2015 | 3 |
| 2013 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypercalcemia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 4 |
| Phase 3 | 5 |
| Phase 4 | 9 |
| Not applicable | 10 |
| Observational | 14 |
How many Hypercalcemia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 29 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypercalcemia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Amgen | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3 |
| Abbott | 1 |
| Chugai Pharma USA | 1 |
Which drugs are being tested for Hypercalcemia? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cinacalcet | 6 |
| Calcium-vitamin D3 | 2 |
| Calcitriol | 2 |
| Calcium/Vitamin D | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Paricalitol | 4 |
| Rifampicin | 2 |
| ARQ197 | 1 |
| Low dose losartan | 1 |
| Alendronate 70mg weekly | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypercalcemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 7 | 3 |
| Hypercalcaemia | 5 | 1 |
| Neutropenia (Neutrophil count decreased) | 5 | 1 |
| Pyrexia | 5 | 3 |
| Acute respiratory failure | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hypercalcemia? (189)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Biochemical Clusters as Substitutes of Bone Biopsies in Kidney Transplant Patients. | Calcified tissue international | 2024 | Yes |
| A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. | The oncologist | 2023 | Yes |
| Case Report: Nine-year-old with parathyroid adenoma within the piriform sinus. | Frontiers in endocrinology | 2023 | Yes |
| Resolution of Secondary Hyperparathyroidism After Kidney Transplantation and the Effect on Graft Survival. | Annals of surgery | 2023 | Yes |
| Safety and tolerability of high-dose daily vitamin D<sub>3</sub> supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes. | European journal of clinical nutrition | 2022 | Yes |
Showing 5 of 189 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.